Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Koenecke, Christian  [Clear All Filters]
2024
Odak I, Bayir LM, Riemann L, Sikora R, Schneider J, Xiao Y, Möhn N, Skripuletz T, Beutel G, Eder M, et al. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time. Front Immunol. 2024;15:1298598.
Penack O, Peczynski C, Boreland W, Lemaitre J, H Reinhardt C, Afanasyeva K, Avenoso D, Holderried TAW, Kornblit BThomas, Gavriilaki E, et al. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party. Bone Marrow Transplant. 2024.
Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, Itälä-Remes M, Corral LLopez, Schaap NPM, Karas M, et al. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12(1).
Penack O, Dreger P, Ajib S, Ayuk F, Baermann B-N, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, et al. Management of Patients undergoing CAR-T cell therapy in Germany. Oncol Res Treat. 2024.
Suvannasankha A, Bahlis N, Trudel S, Weisel K, Koenecke C, Oriol A, Voorhees PM, Alonso AA, Callander NS, Mateos M-V, et al. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer. 2024.
2023
Bader P, Rossig C, Hutter M, Ayuk FAyuketang, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023.
Panagiota V, Kerschbaum JFranziska, Penack O, Stein CM, Arends CM, Koenecke C, Strzelecka PM, Kloos A, Wiegand L, Lasch A, et al. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients. Hemasphere. 2023;7(10):e957.
Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kröger N, Moiseev I, Penack O, Salooja N, Schoemans H, et al. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transplant. 2023.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, Jurado M, Martínez C, Natale A, Pérez-Simón JAntonio, et al. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Front Immunol. 2023;14:1283034.
Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Göhring G, Behrens YLisa, Li Z, et al. Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2023.
Stadler M, Hambach L, Dammann E, Diedrich H, Kamal H, Hamwi I, Schultze-Florey C, Varvenne M, Ehrlich S, Buchholz S, et al. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease. Ann Hematol. 2023.
Gjærde LKlingen, Peczynski C, Polge E, Kröger N, de Latour RPeffault, Finke J, Holler E, Blaise D, Helbig G, Salmenniemi U, et al. Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2023.
Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub-Agha I, Fegueux N, Daskalakis M, Collin M, Dreger P, et al. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Front Immunol. 2023;14:1252811.
Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, Daskalakis M, Kröger N, Dreger P, Besley C, et al. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023;11(4).
Peric Z, Basak G, Koenecke C, Moiseev I, Chauhan J, Asaithambi S, Sagkriotis A, Gunes S, Penack O. Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening Study. JMIR Cancer. 2023;9:e42905.
2022
Sasse S, Bröckelmann PJan, Momotow J, Plütschow A, Hüttmann A, Basara N, Koenecke C, Martin S, Bentz M, Grosse-Thie C, et al. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma. 2022:1-8.
Bethge WAndreas, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EMaria, Wulf GG, Marks R, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.
Perovic V, Sabol I, Grce M, Inngjerdingen M, Pulanic D, Peric Z, Peczynski C, Polge E, Koenecke C, Dickinson A, et al. Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network. Bone Marrow Transplant. 2022.
Moiseev I, Ambron P, Badoglio M, Peczynski C, Basak G, Koenecke C, Schoemans H, Penack O, Peric Z. Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2022.
2021
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, de la Camara R, Glass B, Duarte RF, Kröger N, Schoemans H, Koenecke C, et al. Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. Bone Marrow Transplant. 2021.
Schultze-Florey CR, Kuhlmann L, Raha S, Barros-Martins J, Odak I, Tan L, Xiao Y, Ravens S, Hambach L, Venturini L, et al. Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. Blood Adv. 2021.
Panagiota V, Meggendorfer M, Kubasch ASophie, Gabdoulline R, Krönke J, Mies A, Shaswar R, Kandziora C, Klement P, Schiller J, et al. Impact of PPM1D Mutations in Patients with Myelodysplastic Syndrome and Deletion of Chromosome 5q. Am J Hematol. 2021.
2020
Odak I, Depkat-Jakob A, Beck M, Jarek M, Yu Y, Seidler U, David S, Ganser A, Förster R, Prinz I, et al. Donor-derived IL-17A and IL-17F deficiency triggers Th1 allo-responses and increases gut leakage during acute GVHD. PLoS One. 2020;15(4):e0231222.
Stahl K, Schmidt BMW, Hoeper MM, Skripuletz T, Möhn N, Beutel G, Eder M, Welte T, Ganser A, Falk CS, et al. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. J Crit Care. 2020;57:124-129.

Pages